This is a preview of subscription content, log in via an institution to check access.
Literatur
Robert C et al (2019) Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 381(7):626–636
Schadendorf D et al (2018) Melanoma. Lancet 392(10151):971–984
Gutzmer R et al (2020) Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 395(10240):1835–1844
Nathan PD et al (2020) Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600—mutant unresectable or metastatic melanoma: results from the randomized part 3 of the Phase III COMBI-i trial. Ann Oncol 31(Suppl4):LBA43. https://doi.org/10.1016/j.annonc.2020.08.2273
Ascierto PA et al (2019) Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med 25(6):941–946
Rights and permissions
About this article
Cite this article
Quantensprung durch zielgerichtete und Immuntherapie beim Melanom. best practice onkologie 16, 36–43 (2021). https://doi.org/10.1007/s11654-020-00279-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11654-020-00279-4